ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VRd in NDMM Eligible for ASCT” | VuMedi

Integrity CE

ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VRd in NDMM Eligible for ASCT”

By Integrity CE FEATURING Ola Landgren

By Integrity CE FEATURING Ola Landgren

0 views

January 24, 2024

Comments 0

Login to view comments. Click here to Login